Takeda Chemical Industries, Inc.

Hitachi, Ltd.

Mitsuru Kawada

Isuke Imada

Masazumi Watanabe

Katsumi Kondo

Hirosada Sugihara

Teruo Kitamura

Koichi Matsumura

Hiroshi Morimoto

Yuka Sudo

Yoshihiro Sugihara

Yoshio Sugiyama

Masaaki Tsurushima

Kiyoharu Matsumoto

Yoshitaka Uesugi

Hiroyuki Miya

Takashi Sohda

Hiroyuki Odaka

Akio Mukoh

Mitsuru Shiraishi

Yu Momose

Isao Aoki

Shinji Terao

Toru Yamano

Naohiro Taya

Mari Adachi

Process for producing optically active naphthalene derivative and optical resolver therefor

2,4-Oxazolidinedione derivative represented by the formula: ##STR1## wherein R stands for an optionally substituted hydrocarbon residue or heterocyclic group; Y stands for a group represented by --CO--, --CH(OH)-- or --NR.sup.3 -- (wherein R.sup.3 stands for an optionally substituted alkyl group); m is 0 or 1; n is 0, 1 or 2; A stands for a C.sub.1-7 divalent aliphatic hydrocarbon group; R.sup.1 stands for hydrogen or an alkyl group; ring E stands for a benzene ring having 1 or 2 substituents; L and M respectively stand for hydrogen, or L and M may optionally be combined with each other to form a bond; with a proviso that the partial formula: ##STR2## does not include the formula: ##STR3## wherein R' stands for an alkyl group; or a salt thereof, which has excellent actions of lowering blood sugar and lipid in blood.

Oxazolidinedione derivatives, their production and use

The invention relates to optically active compounds represented by the general formula ##STR1## wherein R.sub.1, R.sub.2, Q.sub.1, Q.sub.2, Q.sub.3, ##STR2## and M are defined as in the specification, methods and intermediates for their preparation, liquid crystal compositions comprising at least one optically active compound of formula I and their use in electrooptical display, switching and modulation devices.

Optically active compounds, liquid crystal compositions comprising said

The invention relates to optically active compounds represented by the general formula I ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, Q.sub.1, Q.sub.2, Q.sub.3, and M are defined as in the specification, methods and intermediates for their preparation, liquid crystal compositions comprising at least one optically active compound of formula I and their use in electrooptical display, switching and modulation devices.

Optically active compounds, liquid crystal composition containing said

Method for producing (2R,3S)-3-hydroxy-2-methylbutyrate by microbial

A (1R,2S)-2-hydroxycycloalkanecarboxylic acid ester is efficiently and selectively produced by microbial asymmetric reduction of a 2-oxocycloalkanecarboxylic acid ester with a bacterial strain or its processed material.

Process for producing optically active 2-hydroxycycloalkanecarboxylic

There are disclosed an optically active compound represented by the general formula: ##STR1## wherein n, R.sub.1, R.sub.2, R.sub.3, R.sub.4, Q.sub.1, Q.sub.2, Q.sub.3, and M are defined as in the detailed explanation, and *-marked carbon atoms are each an asymmetric carbon atom; a liquid crystal composition comprising at least one optically active compound of said general formula and a liquid crystal optical modulator using the composition thereof.

Optically active compound, liquid crystal composition containing said

The present invention discloses dichiral compounds represented by the general formula ##STR1## (R.sub.1, R.sub.2, R.sub.3, R.sub.4, Q.sub.1, Q.sub.2, Q.sub.3, M and n have the same definitions as in the description portion of the specification), intermediates for preparation of said compounds, liquid crystal compositions comprising said compounds, and liquid crystal optical modulators using said compositions.

A compound of the general formul: ##STR1## wherein .alpha. .beta. means a saturated bond or a double bond; each R independently of one another is a methyl group or a methoxy group, or two R's taken together represent a group of --CH.dbd.CH--CH.dbd.CH--; n is zero or an integer of 1 through 9; when .alpha. .beta. is a saturated bond, R.sub.2 is a hydrogen atom or hydroxyl group, and when .alpha. .beta. is a double bond, R.sub.2 is a hydrogen atom; when .alpha. .beta. is a double bond or when R.sub.2 is a hydroxyl group, R.sub.1 is a carboxyl group, a group of CH.sub.2.sub.2m OH (wherein m is an integer of 1 through 3) or a group of ##STR2## (wherein m is an integer of 1 through 3); when .alpha. .beta. is a saturated bond and R.sup.2 is a hydrogen atom, R.sub.1 is a hydroxymethyl group or a group of ##STR3## (wherein m is an integer of 1 through 3) has pharmacological actions such as membrane stabilizing activity (e.g. lysosomal membrane stabilizing activity), mitochondrial electron transport activity, hypotensive activity, activity to inhibit cardiac hypertrophy, tracheal muscle relaxant activity, cerebral circulation improving activity and cerebral ischemia preventive activity and is of value in the prophylaxis and treatment of hypertension, cardiac failure, asthma, cerebral apoplexy and other diseases, as a cardiac failure remedy, bronchodilator, cerebral circulation improving agent or the like.

Quinine derivatines

A process is disclosed for producing a 4-O-sulfonyluracil derivative of the formula ##STR1## [wherein R.sup.1 is hydrogen, halogen, alkyl and alkoxy, R.sup.2 is glycosyl having protected hydroxyls; and --SO.sub.2 R.sup.3 is an organic sulfonyl] which comprises reacting an uracil derivative of the formula ##STR2## [wherein R.sup.1 and R.sup.2 are as defined above] with an organic sulfonylating agent of the formula R.sup.3 SO.sub.2 X [wherein R.sup.3 SO.sub.2 is an organic sulfonyl and X is halogen] in the presence of potassium carbonate. The obtained 4-O-sulfonyluracil is further subjected to amination. The processes are industrially adavantageous and produce cytosine derivatives such as cytidine in high yield.

Conversion of uracil derivatives to cytosine derivatives

A cytosine nucleoside is produced by reacting a peracylcytosine with a hydroxy-protected monosaccharide or a hydroxy-protected nucleoside whose base moiety is other than cytosine and, if necessary, removing the hydroxy-protecting group.

Production of cytosine nucleosides

Novel spirobenzofuranone compounds of the formula: ##STR1## wherein R is a hydrogen atom or a lower alkyl and --X-- is ##STR2## and a pharmaceutically acceptable salt thereof, have gastric secretion inhibitive, antiulcer activities, and are of value as drugs.

Spirobenzofuranones and their use in treating peptic ulcers

Novel compounds of the formulae ##STR1## wherein R represents lower alkyl or lower alkoxy, A represents --CH.sub.2 --, --CO-- or ##STR2## n represents an integer of 1 to 8, X represents hydrogen or hydroxyl which may be protected and Y represents hydroxyl which may be protected, and their esters show an excellent action on the lysosomal membranes of cells, and exhibit excellent pharmacological activities such as physiologic host defense control activity, especially immuno-potentiating activity.

Growing community of inventors

Amagasaki, Japan

Mitsuru Kawada